VOJTISEK, R., E. SUKOVSKA, J. BAXA, Marie BUDÍKOVÁ, P. KOVAROVA a J. FINEK. Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences. STRAHLENTHERAPIE UND ONKOLOGIE. HEIDELBERG: SPRINGER HEIDELBERG, 2019, roč. 195, č. 11, s. 972-981. ISSN 0179-7158. Dostupné z: https://dx.doi.org/10.1007/s00066-019-01491-0.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences
Autoři VOJTISEK, R. (garant), E. SUKOVSKA, J. BAXA, Marie BUDÍKOVÁ (203 Česká republika, domácí), P. KOVAROVA a J. FINEK.
Vydání STRAHLENTHERAPIE UND ONKOLOGIE, HEIDELBERG, SPRINGER HEIDELBERG, 2019, 0179-7158.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Německo
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.899
Kód RIV RIV/00216224:14310/19:00113450
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1007/s00066-019-01491-0
UT WoS 000494072900003
Klíčová slova anglicky Cervical cancer; 3D brachytherapy; Uterovaginal brachytherapy; 3T MRI-guided brachytherapy; Late side effects
Štítky rivok
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 1. 4. 2020 11:48.
Anotace
Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 +/- 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2Gy per fraction (EQD2, range 70.7-97.9Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2cm(rectum)(3)= 62.6 +/- 6.9Gy EQD2 (range 38.2-77.2Gy), D2cm(sigmoid)(3)= 66.2 +/- 6.8Gy EQD2 (43.2-78.6Gy) and D2cm(bladder)(3)= 75.1 +/- 8.3Gy EQD2 (58.2-92.6Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
VytisknoutZobrazeno: 24. 7. 2024 05:21